- Mechanism
- Downregulates IL-6 to reduce inflammaging
- Typical research dose
- 1-3% concentration in topical formulations
- Route
- topical
- Half-life
- Unknown
- Legal status
- Cosmetic Ingredient / Research Only
Overview
Rigin, also known as Palmitoyl Tetrapeptide-7, is a synthetic lipopeptide widely researched for its ability to combat inflammation-driven skin aging. By mimicking the youth hormone DHEA, the Rigin peptide downregulates the production of pro-inflammatory cytokines like Interleukin-6 (IL-6) in the skin. This compound matters because it directly targets inflammaging, helping to preserve collagen and elastin networks while improving overall skin firmness, resilience, and texture.
Potential Benefits
- Reduced Skin Inflammation: Rigin significantly suppresses the secretion of Interleukin-6 (IL-6), mitigating the chronic basal inflammation associated with aging skin.
- Collagen Preservation: By lowering inflammatory cytokines, the peptide prevents the excessive activation of matrix metalloproteinases (MMPs) that degrade structural collagen.
- Improved Skin Elasticity: Clinical research indicates that Rigin benefits the structural integrity of the dermis, leading to firmer, more resilient skin that resists sagging.
- Wrinkle Reduction: Often combined with Palmitoyl Tripeptide-1 in formulations like Matrixyl 3000, it visibly reduces the depth, volume, and density of fine lines.
- Enhanced UV Resilience: Studies suggest it helps protect skin cells from the inflammatory cascade triggered by acute ultraviolet radiation exposure.
- Improved Skin Tone: By reducing chronic erythema and micro-inflammation, the peptide promotes a more even, uniform complexion and reduces visible redness.
Side Effects
Common side effects:
- Mild application site redness
- Temporary skin irritation or tingling
- Dryness or flaking at the application site
- Increased skin sensitivity to other active ingredients
Rare or serious side effects:
- Allergic contact dermatitis
- Severe erythema or swelling
- Post-inflammatory hyperpigmentation from irritation
Rigin is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Cytokine modulation is the primary mechanism by which the Rigin peptide exerts its anti-aging effects. It acts as a DHEA-like molecule, binding to cellular receptors to inhibit the excessive production of Interleukin-6 (IL-6) by keratinocytes and fibroblasts. This targeted suppression interrupts the inflammatory cascade that typically accelerates cellular senescence and tissue degradation in aging skin.
Matrix preservation occurs as a direct downstream effect of this reduced inflammatory state. With lower levels of IL-6, the skin produces fewer matrix metalloproteinases (MMPs), which are enzymes responsible for breaking down the extracellular matrix. Consequently, Palmitoyl Tetrapeptide-7 allows the skin to maintain its natural collagen and elastin reserves, promoting structural stability and reducing visible signs of aging.
Origin & History
Synthetic development of Rigin was pioneered by the French cosmetic active ingredient manufacturer Sederma. Researchers designed Palmitoyl Tetrapeptide-7 by attaching a palmitic acid sequence to a specific four-amino-acid chain (Gly-Gln-Pro-Arg) derived from immunoglobulin G. This lipid modification was a crucial milestone, as it significantly enhanced the peptide's ability to penetrate the lipophilic stratum corneum of the skin.
Regulatory status classifies the Rigin peptide primarily as a cosmetic ingredient rather than a pharmaceutical drug. It is widely utilized in topical anti-aging formulations, most notably as a core component of the patented Matrixyl 3000 complex. While it remains a research-only compound in pure, isolated clinical settings, it is globally approved for use in over-the-counter dermatological and cosmetic applications.